Hims does not directly copy the Novo pill. By personalizing the pill for each individual patient (for example by adding B12, which means it is not a direct copy), the company is operating in a legal grey area, but this makes it possible to enter a new business segment much more cheaply.
Hims  will thus penetrate even further into the segments of the traditional healthcare industry and drive vertical integration. I don't expect a Danish company to win in court against a US company because of a legal gray area.
@Aktienfox What do you think?
Hims  will thus penetrate even further into the segments of the traditional healthcare industry and drive vertical integration. I don't expect a Danish company to win in court against a US company because of a legal gray area.
@Aktienfox What do you think?
•
44
•
@Klein-Anleger well.... think that $LLY is not so happy with the copycat preparations either.
••
1Wk
@Klein-Anleger How do you want to personalize a mass-produced product like a pill?
•
11
•
@Klein-Anleger I doubt that a lawsuit will be successful... as you described! They had the chance to bring a lawsuit against hins for a long time, which they delayed. In addition, they are in the gray area as long as this remains no more than a threat. However, GLP-1 would be normalized out of the business model, i.e. semaglutide, should this be dropped at some point. But liraglutide remains available! Hims reported on this weeks ago and showed statistics confirming that users would also take a worse product, i.e. liraglutide, which they are allowed to sell!
•
44
•
@Olli68 that is a key part of Ham's business model. Personalized medicines
•
33
•@Olli68 Sorry, that was poorly expressed. I meant that the pill does not contain only GLP1 directly, but is modified and combined. This makes it less legally vulnerable.
But basically, this is actually the business model of selling personalized therapies and medicines tailored to the customer...
But basically, this is actually the business model of selling personalized therapies and medicines tailored to the customer...
•
22
•@Olli68 it's just too tricky for me to be honest
••
1Wk
@Klein-Anleger The problem will be that they use semaglutide for this. And only Novo Nordisk is allowed to do that because they have the patent. Compounding means that they have to change the drug for a single person because they are allergic to an ingredient in the original, for example.
Apart from that, they are clearly violating trademark law with their press release by naming Wegovy. They already have a lawsuit pending against Eli Lilly for trademark infringement and misleading advertising.
Apart from that, they are clearly violating trademark law with their press release by naming Wegovy. They already have a lawsuit pending against Eli Lilly for trademark infringement and misleading advertising.
•
11
•
@Aktienfox But maybe now is also the chance. To finally get away from this whole GLP-1 issue. That has always hovered over the share. It would be nice if all the other TOP areas were given more attention now
•
66
•
@Klein-Anleger i believe that Hims doesn't have a chance to sell a new medical drug without FDA approval. Saying that it is a new drug by adding B12 it must go to several years of trials before approval. Or if its a copy it could be finned to bankruptcy in no time.
•
11
•